$7.36▾ 9.25%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+16.2%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Highdebt to assets
Weak
High leverage relative to its assets.
More coming: dilution / share-count creep.
✦ The read
Xeris Biopharma Holdings, Inc.'s earnings-quality signal is not available yet. Revenue is growing strongly year over year. High leverage relative to its assets.
Key numbers
Signals and key numbers are from the fiscal Q4 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.